Our study provides the first evidence that FLZ treatment decreases APP processing by BACE1 and inhibits tau hyperphosphorylation mediated by the Akt/GSK3β pathway, highlighting the potential of FLZ as a therapy agent against AD. The gene discussed is APP; the disease is Alzheimer disease.